Page 72 - Read Online

Machiels JP. Phase II study of everolimus in patients with for precise targeted anti-cancer therapies. Cancer Biol Med
locally advanced or metastatic transitional cell carcinoma of 2014;11:1-19.
the urothelial tract: clinical activity, molecular response, and 89. Warburg O. On the origin of cancer cells. Science
biomarkers. Ann Oncol 2012;23:2663-70. 1956;123:309-14.
71. Houede N, Pourquier P. Targeting the genetic alterations of the 90. Doherty JR, Cleveland JL. Targeting lactate metabolism for
PI3K-AKT-mTOR pathway: its potential use in the treatment cancer therapeutics. J Clin Invest 2013;123:3685-92.
of bladder cancers. Pharmacol Ther 2015;145:1-18. 91. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism:
72. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, current perspectives and future directions. Cell Death Dis
Abdulkadir SA, Giles FJ. Emerging therapeutic targets in 2012;3:E248.
bladder cancer. Cancer Treat Rev 2015;41:170-8. 92. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P.
73. Sun CH, Chang YH, Pan CC. Activation of the PI3K/Akt/ The Warburg effect: Insights from the past decade. Pharmacol
mTOR pathway correlates with tumour progression and Ther 2013;137:318-30.
reduced survival in patients with urothelial carcinoma of the 93. Halestrap AP. The SLC16 gene family - Structure, role
urinary bladder. Histopathology 2011;58:1054-63. and regulation in health and disease. Mol Aspects Med
74. Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, 2013;34:337-49.
Chen YB, Nielsen ME, Gonzalgo ML, Sidransky D, 94. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN,
Schoenberg M, Netto GJ. Expression status and prognostic Halestrap AP. CD147 is tightly associated with lactate
signifi cance of mammalian target of rapamycin pathway transporters MCT1 and MCT4 and facilitates their cell surface
members in urothelial carcinoma of urinary bladder after expression. EMBO J 2000;19:3896-904.
cystectomy. Cancer 2010;116:5517-26. 95. Xiong L, Edwards CK 3rd, Zhou L. The biological function
75. Afonso J, Longatto-Filho A, DA Silva VM, Amaro T, and clinical utilization of CD147 in human diseases: a
Santos LL. Phospho-mTOR in non-tumour and tumour bladder review of the current scientifi c literature. Int J Mol Sci
urothelium: pattern of expression and impact on urothelial 2014;15:17411-41.
bladder cancer patients. Oncol Lett 2014;8:1447-454. 96. Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J,
76. Cancer Genome Atlas Research Network. Comprehensive Queiros O, Preto A, Casal M. Monocarboxylate transporters
molecular characterization of urothelial bladder carcinoma. as targets and mediators in cancer therapy response. Histol
Nature 2014;507:315-22. Histopathol 2014;29:1511-24.
77. Chaffer CL, Weinberg RA. A perspective on cancer cell 97. Zhu C, Pan Y, He B, Wang B, Xu Y, Qu L, Bao Q, Tian F,
metastasis. Science 2011;331:1559-64. Wang S. Inhibition of CD147 gene expression via RNA
78. Hurst DR, Welch DR. Metastasis suppressor genes at the interference reduces tumor cell invasion, tumorigenicity and
interface between the environment and tumor cell growth. Int increases chemosensitivity to cisplatin in laryngeal carcinoma
Rev Cell Mol Biol 2011;286:107-80. Hep2 cells. Oncol Rep 2011;25:425-32.
79. Liu W, Vivian CJ, Brinker AE, Hampton KR, Lianidou E, 98. Zeng HZ, Qu YQ, Liang AB, Deng AM, Zhang WJ, Xiu B,
Welch DR. Microenvironmental Infl uences on Metastasis Wang H. Expression of CD147 in advanced non-small cell
Suppressor Expression and Function during a Metastatic Cell’s lung cancer correlated with cisplatin-based chemotherapy
Journey. Cancer Microenviron 2014;7:117-31. resistance. Neoplasma 2011;58:449-54.
80. Al-Mulla F, Bitar MS, Taqi Z, Yeung K. RKIP: Much 99. Huang Z, Wang L, Wang Y, Zhuo Y, Li H, Chen J, Chen W.
more than Raf kinase inhibitory protein. J Cell Physiol Overexpression of CD147 contributes to the chemoresistance
2013;228:1688-702. of head and neck squamous cell carcinoma cells. J Oral
81. Yesilkanal AE, Rosner MR. Raf kinase inhibitory Pathol Med 2013;42:541-6.
protein (RKIP) as a metastasis suppressor: regulation of 100. Afonso J, Santos LL, Miranda-Goncalves V, Morais A,
signaling networks in cancer. Crit Rev Oncog 2014;19:447-54. Amaro T, Longatto-Filho A, Baltazar F. CD147 and
82. Escara-Wilke J, Yeung K, Keller ET. Raf kinase inhibitor MCT1-potential partners in bladder cancer aggressiveness
protein (RKIP) in cancer. Cancer Metastasis Rev 2012;31:615-20. and cisplatin resistance. Mol Carcinog 2014;doi: 10.1002/
83. Lamiman K, Keller JM, Mizokami A, Zhang J, Keller ET. mc.22222.
Survey of Raf kinase inhibitor protein (RKIP) in multiple 101. Afonso J, Longatto-Filho A, Baltazar F, Sousa N,
cancer types. Crit Rev Oncog 2014;19:455-68. Costa FE, Morais A, Amaro T, Lopes C, Santos LL. CD147
84. Zaravinos A, Chatziioannou M, Lambrou GI, Boulalas I, overexpression allows an accurate discrimination of bladder
Delakas D, Spandidos DA. Implication of RAF and cancer patients’ prognosis. Eur J Surg Oncol 2011;37:811-7.
RKIP genes in urinary bladder cancer. Pathol Oncol Res 102. Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E.
2011;17:181-90. Mechanisms regulating tissue-specifi c polarity of
85. Afonso J, Longatto-Filho A, Martinho O, Lobo F, Amaro T, monocarboxylate transporters and their chaperone CD147
Reis RM, Santos LL. Low RKIP expression associates with in kidney and retinal epithelia. Proc Natl Acad Sci U S A
poor prognosis in bladder cancer patients. Virchows Arch 2005;102:16245-50.
2013;462:445-53. 103. Xue YJ, Lu Q, Sun ZX. CD147 overexpression is a prognostic
86. Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S. factor and a potential therapeutic target in bladder cancer. Med
Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation Oncol 2011;28:1363-72.
of Tumor Cells Chemo-immuno-resistance to Apoptosis. For 104. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F,
Immunopathol Dis Therap 2013;4:79-92. Toldbod HE, Jensen JL, Ulhoi BP, Sengelov L, Jensen KM,
87. Bonavida B. RKIP-mediated chemo-immunosensitization Orntoft TF. Emmprin and survivin predict response and
of resistant cancer cells via disruption of the NF-kappaB/ survival following cisplatin-containing chemotherapy in
Snail/YY1/RKIP resistance-driver loop. Crit Rev Oncog patients with advanced bladder cancer. Clin Cancer Res
2014;19:431-45. 2007;13:4407-14.
88. Phan LM, Yeung SC, Lee MH. Cancer metabolic 105. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T,
reprogramming: Importance, main features, and potentials Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 2 ¦ July 15, 2015 ¦ 65